20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

a study on Pneumococcal Disease Vaccine

Summary

Healthy Volunteers
healthy people welcome
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.

Official Title

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Keywords

Pneumococcal Disease Pneumococcal Infections Vaccines Heptavalent Pneumococcal Conjugate Vaccine 20-valent pneumococcal conjugate vaccine 13-valent pneumococcal conjugate vaccine

Eligibility

You can join if…

  • Male or female infants born at ≥34 weeks of gestation and who are 2 months of age (≥42 to ≤98 days) at the time of consent (the day of birth is considered day of life 1).
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

You CAN'T join if...

  • Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
  • Major known congenital malformation or serious chronic disorder.

Locations

  • Hope Clinical Research not yet accepting patients
    Canoga Park California 91303 United States
  • Superior Research, LLC accepting new patients
    Sacramento California 95831 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT04379713
Phase
Phase 3
Study Type
Interventional
Last Updated